within Pharmacolibrary.Drugs.ATC.N;

model N05CM05_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.124,
    Cl             = 0.97 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00011566666666666667,
    Tlag           = 14400
  );

  annotation(Documentation(
    info ="<html><body><p>Scopolamine is an anticholinergic agent used to prevent motion sickness and postoperative nausea/vomiting. It blocks the action of acetylcholine on smooth muscles, glands, and in the central nervous system.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy males and females after transdermal administration (1.5 mg/patch, delivering approximately 1 mg over 3 days).</p><h4>References</h4><ol><li><p>Pensado, A, Hattam, L, White, KAJ, McGrogan, A, Bunge, AL, Guy, RH, &amp; Delgado-Charro, MB (2021). Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling. <i>Molecular pharmaceutics</i> 18(7) 2714–2723. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.1c00238&quot;>10.1021/acs.molpharmaceut.1c00238</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34124907/&quot;>https://pubmed.ncbi.nlm.nih.gov/34124907</a></p></li><li><p>Renner, UD, Oertel, R, &amp; Kirch, W (2005). Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. <i>Therapeutic drug monitoring</i> 27(5) 655–665. DOI:<a href=&quot;https://doi.org/10.1097/01.ftd.0000168293.48226.57&quot;>10.1097/01.ftd.0000168293.48226.57</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16175141/&quot;>https://pubmed.ncbi.nlm.nih.gov/16175141</a></p></li><li><p>Nachum, Z, Shupak, A, &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200645060-00001&quot;>10.2165/00003088-200645060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16719539/&quot;>https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CM05_1;
